Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site

Autor: Exell, JC, Thompson, MJ, Finger, LD, Shaw, SJ, Debreczeni, J, Ward, TA, McWhirter, C, Siöberg, CLB, Molina, DM, Abbott, WM, Jones, CD, Nissink, JWM, Durant, ST, Grasby, JA

The structure-specific nuclease human flap endonuclease-1 (hFEN1) plays a key role in DNA replication and repair and may be of interest as an oncology target. We present the crystal structure of inhibitor-bound hFEN1, which shows a cyclic N-hydroxyur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::ae4b5d436c9147afb2e3326fcda76a03
https://eprints.whiterose.ac.uk/118189/1/emss-68537.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Propagation de la lumière en milieu aléatoire. Rôle de l'absorption, de la diffusion dépendante et du couplage surface-volume

Autor: Durant, Stéphane

L'étude de la propagation de la lumière à travers un milieu diffusant est un sujet de recherche d'une portée à la fois fondamentale et appliquée : - fondamentale pour l'étude des phénomènes de transport en général; - et appliquée par exem

Externí odkaz: http://tel.archives-ouvertes.fr/tel-00004154
http://tel.archives-ouvertes.fr/docs/00/04/59/19/PDF/tel-00004154.pdf

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.

Autor: Dibitetto D; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri 2, 20156, Milan, Italy. diego.dibitetto@marionegri.it., Liptay M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Vivalda F; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Dogan H; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Gogola E; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., González Fernández M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Duarte A; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Schmid JA; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Decollogny M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Francica P; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Przetocka S; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Durant ST; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK., Forment JV; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK., Klebic I; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Siffert M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., de Bruijn R; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Kousholt AN; Oncode Institute, Amsterdam, The Netherlands.; Biotech Research and Innovation Centre, University of Copenhagen, 2200 N, Copenhagen, Denmark., Marti NA; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Dettwiler M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Sørensen CS; Biotech Research and Innovation Centre, University of Copenhagen, 2200 N, Copenhagen, Denmark., Tille JC; Division of Clinical Pathology, Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Undurraga M; Division of Gynecology, Department of Pediatrics and Gynecology, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Labidi-Galy I; Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Geneva, Switzerland.; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Lopes M; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Sartori AA; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. j.jonkers@nki.nl.; Oncode Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl., Rottenberg S; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. sven.rottenberg@unibe.ch.

Publikováno v: Nature communications [Nat Commun] 2024 May 24; Vol. 15 (1), pp. 4430. Date of Electronic Publication: 2024 May 24.